Rebranding India’s Exclusive Innovator in Peptide Molecules
Background
Issar Pharma is a pioneering research-driven company focused on peptide-based drug discovery and development. With a unique position as one of India’s only dedicated innovators in peptide molecules, Issar needed a brand identity that would reflect its exclusivity, scientific credibility, and market potential.
Challenge
Despite strong R&D and a promising pipeline, Issar lacked a unified brand presence and a go-to-market framework. The company required:
- A complete rebranding exercise to meet global biotech standards.
- Positioning that highlighted its leadership in peptide innovation.
- A marketing function to build commercial readiness for its pipeline.
- Public relations support to gain visibility with stakeholders and the scientific community.
Our Approach
At IMC – InfocusRx Marketing & Communications Pvt. Ltd., we worked with Issar Pharma to transform its identity and establish a market-facing presence. Beyond rebranding, IMC also helped build the foundation for marketing and outreach activities.
Solutions Delivered
- New Brand Identity & Logo – Crafted a modern, science-driven visual identity aligned with peptide innovation.
- Rebranding & Positioning – Positioned Issar as India’s only dedicated peptide drug discovery company.
- Marketing Team Setup – Established and trained a dedicated marketing team to focus on commercializing Issar’s peptide innovation.
- PR & Communication – Designed PR strategies and activities to boost scientific and corporate visibility.
- Marketing Collaterals & Digital Storytelling – Produced assets and narratives to showcase Issar’s research and pipeline.
Impact
- Issar Pharma’s new identity established it as a credible global biotech player.
- Strengthened its reputation as India’s exclusive innovator in peptide therapeutics.
- IMC-enabled marketing team began driving focused outreach for peptide molecule commercialization.
- PR campaigns enhanced recognition among investors, scientists, and partners.
- Culminated in the strategic acquisition of its Genome Valley facility by Bharat Biotech in 2023.
